Overview

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatments:
Galantamine